PowerPoint Presentation

Corporate Presentation

Jeffrey L. Cleland, PhDPresident and Chief Executive OfficerAugust 8 2016

#

1

Company HighlightsOcular Therapeutics Represents a $10B+ Global and Growing MarketGB-102: Dual VEGFR/PDGFR tyrosine kinase inhibitor dosed twice per year(potentially superiority to Eylea and reduced injection frequency)On track for IND in 2017 for wet AMD indication (pre-IND completed)Graybug Visions Patented Technology Solves Key Challenges for Sustained Ocular DeliveryInjection with small gauge needle no surgical procedureMinimal side-effects, no interference with visual axisTunable approach release rate and durationNo inflammation, no toxicity, 6 month in vivo releaseTechnology Enables Broad Portfolio of Ocular ProductsAge-related macular degeneration (wet & dry), glaucoma, neuroprotection, etcNCEs for glaucoma and neuroprotection for 6 month dosing regimenPotential for Product Specific PartnershipsExperienced and Knowledgeable TeamOphthalmology & Drug Delivery Experts

#

2

GB-102 (Sunitinib): Dual VEGFR/PDGFR tyrosine kinase inhibitor (TKI)Sunitinib is the active ingredient in GB-102 and SUTENTOral dosing of SUTENT leads to higher ocular levels than GB-102 without ocular toxicity Oral dosing of SUTENT is effective in mouse CNV model and a patient treated for RCC with anti-VEGF refractory wet AMD (visual acuity improved)Oral doses of SUTENT required for ocular disease leads to systemic adverse events

GB-102 provides sustained intravitreal delivery minimizing systemic exposureA twice per year (or longer) dose interval may increase compliance and sustained levels may increase durability of response Targeting VEGF & PDGF at the receptor level may increase response ratesOpportunity for superiority compared to Eylea (see Fovista results) from a single agentGB-102 (Sunitinib) may become Best in Class Therapy to treat wet AMD

#

3

Injectable High Capacity Reservoir and Localization of Microparticles

BiodegradabilityBiocompatibility BioabsorbabilityPolymer Modified to Reduce InflammationENCAPSULATED DRUG

INTRAVITREAL INJECTION WITH SMALL GAUGE NEEDLEMicroparticleLocalizationDesigned to Aggregate and Remain Outside Visual Axis

FUNDUS PHOTOS, DAY 7

#

4

Toxicokinetics & Safety after Single GB-102 IVT Injection in Pigmented Rabbits10 mg GB-102 (1 mg sunitinib)50 L

Data Supports Twice Per Year DosingWith Comparable Safety to Current Products(Selected tissues)

6ToxicokineticsSafetySingle dose, 6 month non-GLP study in rabbits

Examination by slit-lamp & histology at multiple time points

No evidence of inflammation or toxicity seen in any eyes treated with GB-102 or placebo microparticles

#

5

Long Term Efficacy of GB-102 (Single Dose): Potential for Superiority over AfliberceptGB-102 is potentially better than Eylea with a duration of greater than 3 months

Lowest GB-102 dose is 1/20 Maximum Feasible Dose (1 mg Sunitinib)GB-102 Dose Groups0.5 mg GB-102 (0.05 mg Sunitinib)1 mg GB-102 (0.1 mg Sunitinib)3 mg GB-102 (0.3 mg Sunitinib)

3 months3 wk3 wkAflibercept (Eylea)0.7 mg same day as laser

FluoresceinAngiograms(CNV area)LaserDosingGB-102 Dose 0.5 mg 1.0 mg 3 mg

Sunitinib Dose 0.05 mg 0.10 mg 0.30 mg Aflibercept Placebop < 0.01Rabbit CNV ModelPoster Presentation at AAO 2016

#

6

Company HighlightsOcular Therapeutics Represents a $10B+ Global and Growing MarketGB-102: Dual VEGFR/PDGFR tyrosine kinase inhibitor dosed twice per year(potential for superiority to Eylea and reduced injection frequency)On track for IND in 2017 for wet AMD indication (pre-IND completed)Graybug Visions Patented Technology Solves Key Challenges for Sustained Ocular DeliveryInjection with small gauge needle no surgical procedureMinimal side-effects, no interference with visual axisTunable approach release rate and durationNo inflammation, no toxicity, 6 month in vivo releaseTechnology Enables Broad Portfolio of Ocular ProductsAge-related macular degeneration (wet & dry), glaucoma, neuroprotection, etcNCEs for glaucoma and neuroprotection for 6 month dosing regimenPotential for Product Specific PartnershipsExperienced and Knowledgeable TeamOphthalmology & Drug Delivery Experts

#

7

#